Puma Biotech Rebranding — Alex Maurer Designs
La EMA recomienda no aprobar el fármaco de Puma Biotech
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Resumen: Puma Biotechnology y Pierre Fabre firman acuerdo de licencia exclusiva para desarrollar y comercializar NERLYNX® (neratinib) en Europa | Business Wire
PumaBiotech (@pumabiotech) / Twitter
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Puma Biotech Inc. is looking forward to going to the top - Industry Global News24
Puma Biotech Rebranding — Alex Maurer Designs
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
ICOMPRE 2 DE CADA CAJA puma biotechnology jobs Y OBTENGA UN 70% DE DESCUENTO!
El negocio bursátil de PUMA BIOTECHNOLOGY – Observatorio de biopolitica
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma Biotechnology
Puma Biotechnology Surging
